Vesper Bio

Vesper Bio, backed by Lundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical unmet medical needVES001 is a product designed with the needs of the patients and their care givers in mindThe Phase I study will assess safety, tolerability and pharmacokinetics and target engagement biomarkers across a range of single and multiple doses, moving on to a Phase Ib/c Proof of ConceptView original content:https://www.prnewswire.co.uk/news-releases/vesper-bio-doses-first-volunteer-in-phase-i-study-of-first-in-class-oral-treatment-for-frontotemporal-dementia-ftd-302007864.html